AstraZeneca Pharma India has received marketing approval from the Drugs Controller General of India (DCGI) for its product Tagrisso (Osimertinib) for the treatment of non-small cell lung cancer. This approval will provide better medicine for the management of non-small cell lung cancer, which can help patients attain a better quality of life.
Osimertinib is an oral pill that has shown to decrease the risk of cancer recurrence by nearly 83% when given to patients of lung cancer whose tumour has a specific mutation called EGFR mutation and who have undergone surgical removal of the lung tumour.
According to the Global Cancer Survey (GLOBOCAN), in 2018, the total number of new lung cancer cases was 67,795, and 63,475 deaths were reported. With the approval of Tagrisso, patients suffering from non-small cell lung cancer in India will have access to an effective treatment option that can improve their chances of recovery.
The approval of Tagrisso is a significant milestone for AstraZeneca Pharma India, as it demonstrates the company’s commitment to providing innovative and effective treatments for patients suffering from cancer. The company’s Managing Director, Gagandeep Singh Bedi, said in a statement that the regulatory approval of Tagrisso in India will provide better medicine for the management of non-small cell lung cancer and help patients attain a better quality of life.
AstraZeneca Pharma India is part of the global biopharmaceutical company AstraZeneca, which is committed to discovering, developing, and delivering innovative treatments for patients around the world. The company’s mission is to make a meaningful difference in the lives of patients by developing innovative medicines that help them fight serious illnesses.
In conclusion, the approval of Tagrisso is a significant achievement for AstraZeneca Pharma India, and it demonstrates the company’s commitment to providing innovative and effective treatments for patients suffering from cancer. This approval is a positive development for patients suffering from non-small cell lung cancer in India, as it provides them with an effective treatment option that can improve their chances of recovery and help them attain a better quality of life.